Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
Verhoeven MMA, Tekstra J, Welsing PMJ, Pethö-Schramm A, Borm MEA, Bruyn GAW, Bos R, Griep EN, Klaasen R, van Laar JM, Lafeber FPJG, Bijlsma JWJ, de Hair MJH, Jacobs JWG.
Verhoeven MMA, et al.
Rheumatology (Oxford). 2020 Sep 1;59(9):2325-2333. doi: 10.1093/rheumatology/kez602.
Rheumatology (Oxford). 2020.
PMID: 31859346
Free PMC article.
Clinical Trial.